DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) was downgraded by equities researchers at Morgan Stanley from an "overweight" rating to an "equal weight" rating in a research report issued on Tuesday, MarketBeat reports. They currently have a $14.00 price objective on the medical instruments supplier's stock. Morgan Stanley's price target suggests a potential upside of 9.12% from the company's current price.
Other equities analysts have also recently issued reports about the stock. Evercore ISI reaffirmed an "in-line" rating and set a $20.00 price target on shares of DENTSPLY SIRONA in a research note on Tuesday, January 7th. StockNews.com lowered shares of DENTSPLY SIRONA from a "buy" rating to a "hold" rating in a research report on Friday, February 28th. Wells Fargo & Company reduced their price target on shares of DENTSPLY SIRONA from $20.00 to $19.00 and set an "equal weight" rating for the company in a research report on Friday, February 28th. Robert W. Baird lowered their price target on DENTSPLY SIRONA from $22.00 to $20.00 and set a "neutral" rating on the stock in a report on Friday, February 28th. Finally, Barrington Research reduced their price objective on DENTSPLY SIRONA from $24.00 to $20.00 and set an "outperform" rating for the company in a report on Friday, February 28th. Thirteen research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $22.58.
Check Out Our Latest Research Report on DENTSPLY SIRONA
DENTSPLY SIRONA Stock Performance
NASDAQ XRAY traded up $0.18 on Tuesday, hitting $12.83. 2,841,795 shares of the company's stock were exchanged, compared to its average volume of 2,959,776. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.25 and a quick ratio of 0.84. DENTSPLY SIRONA has a fifty-two week low of $12.16 and a fifty-two week high of $31.00. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of -6.20, a P/E/G ratio of 1.80 and a beta of 0.92. The firm's 50-day moving average price is $15.72 and its two-hundred day moving average price is $18.82.
Insider Activity
In other DENTSPLY SIRONA news, Director Gregory T. Lucier purchased 15,142 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was acquired at an average cost of $16.51 per share, with a total value of $249,994.42. Following the acquisition, the director now owns 81,971 shares of the company's stock, valued at approximately $1,353,341.21. This represents a 22.66 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.52% of the company's stock.
Hedge Funds Weigh In On DENTSPLY SIRONA
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Nordea Investment Management AB boosted its position in DENTSPLY SIRONA by 245.0% during the 4th quarter. Nordea Investment Management AB now owns 251,556 shares of the medical instruments supplier's stock valued at $4,754,000 after purchasing an additional 178,639 shares during the period. JPMorgan Chase & Co. lifted its stake in DENTSPLY SIRONA by 206.3% in the third quarter. JPMorgan Chase & Co. now owns 1,847,389 shares of the medical instruments supplier's stock valued at $49,990,000 after buying an additional 1,244,326 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of DENTSPLY SIRONA by 27.9% during the fourth quarter. Bank of New York Mellon Corp now owns 2,403,110 shares of the medical instruments supplier's stock valued at $45,611,000 after acquiring an additional 523,692 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of DENTSPLY SIRONA by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,101,133 shares of the medical instruments supplier's stock worth $39,880,000 after acquiring an additional 35,360 shares during the last quarter. Finally, Barclays PLC increased its holdings in shares of DENTSPLY SIRONA by 21.8% in the 3rd quarter. Barclays PLC now owns 306,809 shares of the medical instruments supplier's stock worth $8,301,000 after acquiring an additional 54,920 shares during the period. 95.70% of the stock is currently owned by institutional investors and hedge funds.
About DENTSPLY SIRONA
(
Get Free Report)
DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.
See Also
Before you consider DENTSPLY SIRONA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DENTSPLY SIRONA wasn't on the list.
While DENTSPLY SIRONA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
